Great Progress, but Concerns Persist About Cancer Care in America

Episode Summary

Executive Summary: This episode examines ASCO’s 2016 State of Cancer Care report with Julie Vos, highlighting both meaningful progress and persistent gaps in U.S. oncology. The discussion covers advances in immuno-oncology and survivorship, but also inequities by race, geography, and income; limited screening options; immature precision medicine applications; funding constraints; workforce strain; and the unresolved challenge of making cancer care affordable without stifling innovation.

Main Topics: Progress in cancer treatment and survivorship (Priority: 5/5): Vos describes major gains in cancer outcomes, especially from new FDA-approved therapies and immuno-oncology approaches that harness the immune system, leading to better survival and longer remission for some patients. Persistent disparities in cancer incidence and mortality (Priority: 5/5): The conversation emphasizes inequities by race, ethnicity, rurality, economics, and lifestyle, with access to care and social determinants contributing alongside biology. Screening limits and the uncertain role of liquid biopsies (Priority: 4/5): Standard screening remains limited to a few cancers, with liquid biopsies still considered research tools rather than standard screening methods. Precision medicine and the data-to-action gap (Priority: 4/5): While genomic testing is expanding, Vos notes that oncology is still generating more data than it can yet translate into routine, actionable treatment decisions outside clinical trials. Research funding and the cancer moonshot (Priority: 4/5): Funding remains insufficient, and additional public and private investment is presented as essential to capitalize on scientific advances and prioritize high-impact research. Affordability, payment reform, and workforce pressure (Priority: 5/5): The interview addresses rising drug and care costs, emerging value-based payment models, and an aging population that is increasing patient volume despite a relatively flat oncology workforce.

Key Arguments: Cancer progress is real but uneven: survival has improved in many cancers, yet some mortality rates remain flat or have worsened. Immuno-oncology is one of the most promising areas because it uses the patient’s immune system and is already improving survivorship and remission in some cases. Cancer disparities stem from multiple interacting factors, including genetics, environment, lifestyle, and unequal access to care. Liquid biopsies are not yet a standard screening tool; most cancer screening remains limited and cancer-type specific. Precision medicine is advancing in genomics, but the field still lacks enough evidence to make it routine standard of care across cancers. Research funding remains inadequate, and moonshot-style investment could help prioritize the most important scientific questions. ACA coverage expansion helped more people access care, but narrow networks can still block access to academic cancer centers. Value-based payment may eventually improve quality and outcomes, but it has not yet fully taken hold in oncology. The oncology workforce is strained by an aging population and longer survival, requiring more teamwork with advanced practice providers and primary care. Technology has not yet reduced burden in practice; electronic medical records may actually add workload. Drug pricing reforms so far have produced minimal impact, and the current system is described as unsustainable. Affordable cancer care will require collaboration across providers, payers, pharma, and trial design to reduce development costs and preserve innovation.

Data Points: Podcast sponsor event date: October 15th and 16th, 2025 - Prevail Infoworks sponsorship mention Conference edition: 17th Annual Outsourcing and Clinical Trials New England conference - Prevail Infoworks sponsor promotion Report year: 2016 - ASCO State of Cancer Care in America report discussed in interview Approved therapies in 2015: Several new medications - Julie Vos notes new FDA-approved treatments entered use in 2015 Cancer disease burden: Thousands of different diseases - Used to explain why progress varies widely by cancer type Screening example: Low-dose CT scans - Cited as an approved screening tool for long-time smokers Population trend: Aging population with increasing cancer incidence and longer survivorship - Used to explain workforce strain Workforce trend: Stable oncology workforce - Volume is growing faster than clinician supply

Pivotal Quotes: "Cancer is not one disease. It's thousands of different diseases." — Julie Vos: Explaining why progress varies across cancer types and why more research is needed "I think there is a point where we have a large generation of data but don't know what to do with it at this point." — Julie Vos: On the current limits of precision medicine and genomics-driven care "The system is going to have to look at that because it's just an unsustainable system right now." — Julie Vos: On drug prices, value, and the economics of cancer care

Implications: The episode suggests oncology’s scientific progress is outpacing the system’s ability to deliver equitable, affordable care. Future gains will depend on better evidence, more funding, workforce redesign, and payment models that reward value without limiting access or innovation.